Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Key Points

• HC Wainwright raised its Arrowhead Pharmaceuticals price target to $120 from $115 and maintained a “buy” rating, implying 40.34% upside from the prior close.
• Analyst sentiment is broadly positive: nine analysts rate the stock a Buy, three a Hold and one a Sell, resulting in a consensus “Moderate Buy” rating and $97.33 average target.
• Arrowhead reported quarterly revenue of $75.25 million, up 171% year over year and above estimates, but missed earnings expectations with a loss of $1.36 per share versus the projected $1.23 loss.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) had its price target increased by investment analysts at HC Wainwright from $115.00 to $120.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 40.34% from the stock's previous close.

A number of other analysts also recently weighed in on ARWR. Piper Sandler restated an "overweight" rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Sanford C. Bernstein boosted their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a "market perform" rating in a research note on Wednesday, May 13th. Stifel Nicolaus initiated coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a "buy" rating and a $98.00 price objective on the stock. Chardan Capital raised their target price on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a "buy" rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings lowered Arrowhead Pharmaceuticals from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Wednesday, May 20th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $97.33.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR traded down $1.40 during trading hours on Thursday, reaching $85.51. 469,155 shares of the stock traded hands, compared to its average volume of 2,446,180. The company has a market cap of $12.04 billion, a P/E ratio of -38.02 and a beta of 1.27. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The company's 50-day moving average price is $79.63 and its two-hundred day moving average price is $71.16. Arrowhead Pharmaceuticals has a 52-week low of $15.01 and a 52-week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 57.65%. The company had revenue of $75.25 million for the quarter, compared to analysts' expectations of $44.17 million. During the same period in the previous year, the business posted ($1.26) earnings per share. The business's revenue was up 171.0% on a year-over-year basis. On average, analysts anticipate that Arrowhead Pharmaceuticals will post -3.11 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the company's stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the sale, the director owned 52,012 shares in the company, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in Arrowhead Pharmaceuticals by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company's stock valued at $216,799,000 after purchasing an additional 133,921 shares during the period. Baker BROS. Advisors LP increased its holdings in Arrowhead Pharmaceuticals by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company's stock valued at $144,441,000 after purchasing an additional 504,883 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Arrowhead Pharmaceuticals by 0.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company's stock valued at $138,619,000 after purchasing an additional 6,264 shares during the period. Fred Alger Management LLC lifted its stake in Arrowhead Pharmaceuticals by 497.4% during the fourth quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company's stock worth $121,693,000 after purchasing an additional 1,526,164 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source